The Company is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops small molecule drugs including endometriosis treatments, uterine fibroids treatments, cancer immunotherapy drugs; and new biopharmaceuticals including hemophilia treatments, and others. The Company was established on December 6, 2016. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on November 22, 2019.
Headquarters
4th Floor, 49, Daewangpangyo-ro 644beon-gil Bundang-gu Seongnam-si Gyeonggi
Seongnam; Gyeonggi;
Contact Details: Purchase the Tium Bio Co.,Ltd. report to view the information.
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service